By
John Mendelsohn, MD, Past President, The University of Texas M. D. Anderson Cancer Center
Co-Director, Institute for Personalized Cancer Therapy
Houston, TX
Peter Howley, MD, Professor and Chairman, Department of Pathology, Harvard Medical School, Boston, MA
Mark Israel, MD, Director, Norris Cotton Cancer Center; Professor of Pediatrics and Genetics, Dartmouth Medical School, Hanover, NH
Joe Gray, PhD, Director, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA
Craig Thompson, MD, Director, Abramson Cancer Center; Professor of Medicine, University of Pennsylvania, Philadelphia, PA
John Mendelsohn, MD, Past President, The University of Texas M. D. Anderson Cancer Center
Co-Director, Institute for Personalized Cancer Therapy
Houston, TX
Peter Howley, MD, Professor and Chairman, Department of Pathology, Harvard Medical School, Boston, MA
Mark Israel, MD, Director, Norris Cotton Cancer Center; Professor of Pediatrics and Genetics, Dartmouth Medical School, Hanover, NH
Joe Gray, PhD, Director, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA
Craig Thompson, MD, Director, Abramson Cancer Center; Professor of Medicine, University of Pennsylvania, Philadelphia, PA
Description
Successfully fighting cancer starts with understanding how it begins. This thoroughly revised 3rd Edition explores the scientific basis
for our current understanding of malignant transformation and the pathogenesis and treatment of cancer. A team of leading experts thoroughly
explain the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical
trials and practice. Incorporating cutting-edge advances and the newest research, the book provides thorough descriptions of everything
from molecular abnormalities in common cancers to new approaches for cancer therapy. A new full-color format expedites reference, and
now as an Expert Consult title, it enables you to conveniently search the entire text online, download all of the book’s images for your
personal use, and review periodic updates.
Audience:
Oncology and Hematology
